Infectious disease treatment fails less often because drugs are weak than because daily routines are hard. Two recent trials, one in HIV and one in tuberculosis (TB), approach that reality from different directions.
Injectables for people who struggle with daily pills
The ACTG LATITUDE (A5359) study, published in the New England Journal of Medicine, tested long-acting injectable therapy in adults with HIV who face adherence challenges. Participants first achieved viral suppression after structured adherence support, then were randomized to injectable cabotegravir plus rilpivirine or daily oral antiretroviral therapy.
Regimen failure occurred in 22.8% of those on the long-acting injection and 41.2% of those on daily oral treatment. That gap is large enough to influence how clinicians think about people who find daily dosing difficult. You can read more in the report on ACTG LATITUDE study findings.
Choosing the best TB regimen, not just a drug
In TB, BioVersys has dosed the first participant in a Phase 2b regimen-selection study of alpibectir-ethionamide (AlpE) for drug-susceptible pulmonary tuberculosis. The study belongs to the EU-funded UNITE4TB platform and runs at several African clinical sites.
During the initial phase, AlpE is combined with rifampicin, pyrazinamide and ethambutol. Patients then move to continuation therapy with rifampicin and isoniazid. The goal is to identify optimized treatment regimens, with results expected later in the decade. The announcement of the first patient dosed in the AlpE TB trial lays out the design.
BioVersys’s separate tuberculosis trial results have also been published in the New England Journal of Medicine, which highlights progress toward improved treatment strategies.
The shared lesson
LATITUDE changes the delivery method to fit a patient’s life. The AlpE study changes how regimens are chosen and compared, so the best combination is selected on evidence. Both treat real-world feasibility as part of the science rather than an afterthought.
Questions that remain
For long-acting HIV therapy, the open question is how broadly such injections can be delivered to those who would benefit. For TB, it is which regimen comes out ahead when results arrive. Both depend on sustained trial capacity in the places where these diseases are most common.
Equity runs through both stories. Daily pills assume reliable access to pharmacies and stable routines, and multi-site TB platforms assume sustained funding and local expertise. Trials that run across varied settings, including the African sites in the AlpE study, produce evidence that applies more widely.
Conclusion
Better outcomes in HIV and TB won’t come only from new molecules. They will also come from trials that ask how treatment fits into daily life, and then build the answer into the design.
This article is educational and does not replace individualized medical advice, diagnosis or treatment.
Keep your momentum.
Use the next and previous guide controls to continue through connected health topics.



